IGC Pharma, Inc.: Form 10-KT, filed Mar 18, 2026
Filed with the SEC on Mar 18, 2026 and accepted by EDGAR at Mar 18, 2026, 16:02 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 9 months2025-04-01 to 2025-12-31 | $869.0k | us-gaap:Revenues |
| Cost of revenue | 9 months2025-04-01 to 2025-12-31 | $572.0k | us-gaap:CostOfRevenue |
| Gross profit | 9 months2025-04-01 to 2025-12-31 | $297.0k | us-gaap:GrossProfit |
| Research and development | 9 months2025-04-01 to 2025-12-31 | $3.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 9 months2025-04-01 to 2025-12-31 | $4.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 9 months2025-04-01 to 2025-12-31 | −$7.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 9 months2025-04-01 to 2025-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 9 months2025-04-01 to 2025-12-31 | −$4.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 9 months2025-04-01 to 2025-12-31 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 9 months2025-04-01 to 2025-12-31 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 9 months2025-04-01 to 2025-12-31 | 88,851,556 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-04-01 to 2025-12-31 | −$4.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-04-01 to 2025-12-31 | $49.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-12-31 | $900.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $1.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $9.7m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $2.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $2.3m | us-gaap:Liabilities |
| Long-term debt | At period end2025-12-31 | $131.0k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2025-12-31 | $3.0k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2025-12-31 | $7.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001185185-26-000941. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.